KD : A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cgvhd) - Pharmacodynamics and Updated Results
|
|
- Felicity Gallagher
- 5 years ago
- Views:
Transcription
1 KD : A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cgvhd) - Pharmacodynamics and Updated Results Madan Jagasia 1, Amandeep Salhotra 2, Carlos R. Bachier 3, James Essell 4, Daniel J. Weisdorf 5, Behyar Zoghi 6, Aleksandr Lazaryan 5, Laurie S. Green 7, Olivier Schueller 7, Alexandra Zanin-Zhorov 7, Jonathan M. Weiss 7, David Eiznhamer 7, Sanjay K. Aggarwal 7, Bruce R. Blazar 8 and Stephanie J. Lee 9 1 Vanderbilt University, Nashville, TN; 2 City of Hope, Duarte, CA; 3 Sarah Cannon Research Institute, Nashville, TN; 4 Oncology/Hematology Care, Cincinnati; 5 University of Minnesota, Minneapolis, MN; 6 Texas Transplant Institute, Methodist Hospital, San Antonio, TX; 7 Kadmon Corporation, LLC, New York, NY; 8 Division of Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN; 9 Fred Hutchinson Cancer Research Center, Seattle, WA ASH Annual Meeting, December 2018 Kadmon Holdings, Inc. 1
2 Pathophysiology of Chronic GVHD (cgvhd) cgvhd is Driven by Immune Cells and Pro-inflammatory Cytokines cgvhd involves both T cells and B cells Characterized by overproduction of pro-inflammatory cytokines IL-21 and IL-17 Over-activation of pro-inflammatory T follicular helper (Tfh) cells and B cells, leading to overproduction of antibodies Simultaneously causes deficiency of regulatory T (Treg) cells, leading to a lack of appropriate regulation of immune response Combination of T cell and B cell dysfunction leads to cgvhd Blood,
3 ROCK2 Plays Key Role in Autoimmunity and Inflammation ROCK2 Inhibition Rebalances Immune Response to Treat Immune Dysfunction Rho-associated coiled-coil kinase (ROCK) mediates a wide range of functions, including cell movement, shape, differentiation and function 1 Two isoforms exist: ROCK1 and ROCK2 1 ROCK2 inhibition: Reduces STAT3 phosphorylation and increases STAT5 phosphorylation 2,3 Downregulates TH17 responses and increases Treg function, helping to resolve immune dysregulation 2,3 ROCK2 Activation ROCK2 Inhibition STAT3 (TH17) Inflammation STAT5 (Treg) STAT3 (TH17) STAT5 (Treg) RORgt IRF4 Resolution Inflammation Resolution 1 Small GTPases, 2014; 2 Proc Natl Acad Sci, 2014; 3 Blood,
4 ROCK is an Intercellular Integrator of Pro-Fibrotic Signals ROCK Regulates Multiple Profibrotic Processes, Including Myofibroblast Activation ROCK is downstream of major pro-fibrotic mediators, including: Matrix stiffness Transforming growth factor beta (TGF-β) Matrix stiffness Myofibroblast Cell Stress fiber formation Lysophosphatidic acid (LPA) ROCK regulates fibroblast differentiation to myofibroblasts, a pathological cell type in fibrosis ROCK ROCK mediates stress fiber formation MKL1 ROCK regulates transcription of profibrotic genes, including: Connective tissue growth factor (CTGF) MKL1 MKL1 CTGF Alpha-smooth muscle actin (α-sma) Am J Pathol Apr;185(4):
5 KD025 Reduced cgvhd Severity in Preclinical Models KD025 Reduced Skin Pathology Scores, Epidermal Hyperplasia and Keratosis Skin GVHD Score Skin Vehicle (Day 51) KD025 (Day 51) Vehicle KD025 KD025 Reduced Pathology Scores, Based on Organ Histology (D60) Flynn, Blazar et al, Blood 2016 BM BM + KD025 BM BM + KD025 BM BM + KD025 T cells T cells T cells cgvhd cgvhd cgvhd KD025-treated Mice Challenged with Murine CMV Mounted an Antiviral Immune Response 5
6 KD : Design and Key Endpoints Key Eligibility Criteria: Adults with steroiddependent or steroidrefractory cgvhd Have persistent active cgvhd after at least 2 months of steroid therapy Receiving glucocorticoid therapy +/- calcineurin inhibitor therapy for cgvhd No more than 3 prior lines of treatment for cgvhd Cohort 1: 200mg QD (n=17) Cohort 2: 200mg BID (n=16) Cohort 3: 400mg QD (n=21) Three cohorts enrolled sequentially, following safety assessment of previous cohort Key Endpoints: ORR, per 2014 NIH criteria Safety and tolerability of KD025 in patients with cgvhd Duration of response (DOR) Response by organ system Changes in corticosteroid and calcineurin inhibitor dose All data as of 13 September,
7 KD : Baseline Characteristics 48% of all patients had 4 organs affected Included both inflammatory and fibrotic manifestations 67% of all patients had received 2 prior lines of cgvhd therapy Baseline Characteristics Cohort 1 (n=17) Cohort 2 (n=16) Cohort 3 (n=21) Median age (years (range)) 50 (20-63) 55 (30-75) 46 (25-75) Male/Female (%/%) 76/24 56/44 57/43 Median time cgvhd diagnosis to study (months) Organ Involvement 4 organs involved 8 (47) 10 (63) 8 (38) Eyes 14 (82) 11 (69) 17 (81) Skin 13 (76) 12 (75) 15 (71) Mouth 13 (76) 11 (69) 11 (52) Joints and fascia 12 (71) 11 (69) 10 (48) Lungs 3 (18) 3 (19) 11 (52) Upper GI 2 (12) 4 (25) 2 (10) Esophagus 2 (12) 0 (0) 5 (24) Lower GI 1 (6) 2 (13) 1 (5) Liver 0 (0) 2 (13) 0 (0) Severe cgvhd 1 12 (71) 14 (88) 16 (76) Prior Therapies 2 Cohort 1 (n=17) Cohort 2 (n=16) Cohort 3 (n=21) Median prednisone dose at BL (mg/kg/day) Prior Lines of Therapy Median prior lines of therapy (n (%)) 15(88) 9(56) 12(57) Prior Therapies Corticosteroids 17(100) 16(100) 21(100) Sirolimus 10(59) 9(56) 7(33) Tacrolimus 8(47) 6(38) 11(52) Rituximab 8(47) 3(19) 5(24) MMF 4(24) 4(25) 4(19) Cyclosporin 3(18) 0(0) 2(10) Methotrexate 1(6) 2(13) 0(0) Ibrutinib 1(6) 0(0) 2(10) Ixazomib 1(6) 1(6) 0(0) Others for 1 patient each: Anti Thymocyte Globulin, Imatinib, Ofatumumab, Ruxolitinib, Ibrutinib/Placebo 1 Defined as at least 1 organ with NIH Activity Assessment score of 3, or lung score of 2 or 3, at baseline 2 ECP was not counted as a prior systemic therapy 7
8 KD : Patient Disposition 20 Patients Continuing Treatment with KD025 Cohort 1 Cohort 2 Cohort 3 17 patients enrolled Median treatment duration: 37 weeks 16 patients enrolled Median treatment duration: 33 weeks 21 patients enrolled Median treatment duration: 27 weeks 5 cgvhd Progression 10 cgvhd Progression 3 cgvhd Progression 6 Withdrawal 3 Withdrawal 7 Withdrawal 2 Relapse underlying cancer 2 AEs (headache, diarrhea) 1 Voluntary withdrawal 1 Noncompliance 2 Voluntary withdrawal 1 Investigator decision 3 Voluntary withdrawal 2 Death 1 Relapse underlying cancer 1 Investigator decision 6 Active Median treatment duration: 89 weeks 3 Active Median treatment duration: 68 weeks 11 Active Median treatment duration: 34 weeks 8
9 KD : Safety and Tolerability No treatment-related SAEs No apparent increased risk of infection AEs were overall consistent with those expected in cgvhd patients receiving corticosteroids Safety Overview, n (%) Median weeks of treatment Cohort 1 (n=17) Cohort 2 (n=16) Cohort 3 (n=21) ITT (n=54) Any Adverse Event (AE) 16 (94) 16 (100) 19 (90) 51 (94) Grade 3 / 4 AE 10 (59) 10 (63) 9 (43) 29 (54) SAE 5 (29) 6 (38) 9 (43) 20 (37) Drug related AE Any related AE 6 (35) 9 (56) 9 (43) 24 (44) Related AE leading to discontinuation 2 (12) (4) Related Grade 3 / 4 event 2 (12) 4 (25) 2 (10) 8 (15) Related SAE On Study Deaths (14) 2 3 (6) 1 Headache; Diarrhea 2 Relapse of Leukemia; Lung infection; Cardiac arrest. All considered not related to KD025 Commonly Reported AEs, n (%) All Grade, in 15% Cohort 1 (n=17) Cohort 2 (n=16) Cohort 3 (n=21) ITT (n=54) Upper respiratory tract infection 5 (29) 6 (38) 3 (14) 14 (26) ALT / AST increased 6 (35) 4 (25) 3 (14) 13 (24) Fatigue 5 (29) 3 (19) 5 (24) 13 (24) Nausea 6 (35) 2 (13) 5 (24) 13 (24) Diarrhea 6 (35) 2 (13) 4 (19) 12 (22) Anemia 5 (29) 4 (25) 1 (5) 10 (19) GGT increased 4 (24) 5 (31) 1 (5) 10 (19) Cough 1 (6) 3 (19) 5 (24) 9 (17) Dyspnea 2 (12) 5 (31) 2 (10) 9 (17) Hypertension 5 (29) 2 (13) 2 (10) 9 (17) Hyperuricemia 3 (18) 1 (6) 5 (24) 9 (17) Grade 3 / 4, in 5% GGT increased 3 (18) 3 (19) 0 6 (11) Hyperglycemia 2 (12) 0 2 (12) 4 (7) Anemia 2 (12) 1 (6) 0 3 (6) Dyspnea 1 (6) 1 (6) 1 (5) 3 (6) Infection, All Grade, in 5% Upper respiratory tract infection 5 ( 29) 6 ( 38) 3 ( 14) 14 (26) Pneumonia 2 ( 12) 2 ( 13) 0 4 (7) Influenza 2 ( 12) 1 ( 6) 0 3 (6) Oral candidiasis 2 ( 12) 1 ( 6) 0 3 (6) Sinusitis 1 ( 6) 1 ( 6) 1 ( 5) 3 (6) 9
10 Overall Response Rate KD : Overall Response Rate (ORR) ORR (ITT Population) Responses Achieved Across Key Patient Subgroups ORR Cohort 1 (n=17) 65% (11/17) Cohort 2 (n=16) 63% (10/16) Cohort 3 (n=21) 52% 1 (11/21) 80% 70% 60% 59% 58% 62% 55% 50% 95% CI (41, 83) (39, 82) (32, 72) 40% 1 Three patients in Cohort 3 did not reach first response assessment. On a response-evaluable basis, Cohort 3 ORR = 61% (11/18) 30% 20% 10% 0% ITT 2 Prior prior lines of of therapy 4 Organs organs Involved involved Severe cgvhd (n=54) (n=36) (n=26) (n=42) 10
11 KD : Responses Across Organ Systems Responses observed across all affected organ systems Complete responses (CRs) in upper GI, lower GI, mouth, joints/fascia, esophagus, eyes, liver and skin 2 Partial responses (PRs) in lung Organ Involved n (%) Responders (n=32) CR n (%) PR n (%) ORR n (%) Upper GI 7(22) 7(100) 0(0) 7(100) Lower GI 3(9) 3(100) 0(0) 3(100) Mouth 21(66) 11(52) 5(24) 16(76) Joints and fascia 20(63) 1(5) 13(65) 14(70) Esophagus 3(9) 2(67) 0(0) 2(67) Eyes 27(84) 6(22) 9(33) 15(56) Liver 2(6) 1(50) 0(0) 1(50) Skin 22(69) 5(23) 5(23) 10(45) Lungs 10(31) 0(0) 2(20) 2(20) 11
12 KD : Duration of Response (DOR) Responses Achieved with KD025 Are Durable Responses were rapid: 75% of responders have achieved a response at the first assessment (8 weeks) Amongst responders: Kaplan-Meier median DOR of 28 weeks in ITT responder population Responders with sustained responses for 20 weeks: Cohort 1: 9/11 (82%) Cohort 2: 5/10 (50%) Cohort 3: 4/11 (36%) Durability data continue to mature Duration of Response ITT Responders (n=32) Weeks Number at risk
13 KD : Lee cgvhd Symptom Scale (LSS) Score 72% of Responders Experienced Clinically Meaningful Improvement in Symptoms 1 Cohort 1 (%) Cohort 2 (%) Cohort 3 (%) Patients with improvement in LSS Score 11/17 (65) 9/16 (56) 11/21 (52) Responders with improvement in LSS Score 9/11 (82) 5/10 (50) 9/11 (82) Non-Responders with improvement in LSS Score 2/6 (33) 4/6 (67) 2/10 (20) 1 Clinically meaningful improvement ( 7 point reduction) in LSS score 13
14 KD : Corticosteroid and Tacrolimus Dose Reductions 7 Patients Have Completely Discontinued Steroids Cohort 1 (%) Cohort 2 (%) Cohort 3 (%) % reduction in median corticosteroid dose 44% 23% 10% Patients with corticosteroid dose reduction 13/17 (76) 9/16 (56) 15/21 (71) Responders with corticosteroid dose reduction 8/11 (73) 5/10 (50) 10/11 (91) Non-Responders with corticosteroid dose reduction 5/6 (83) 4/6 (67) 5/10 (50) Corticosteroid discontinuations 4/17 (24) 1/16 (6) 2/21 (10) Patients with tacrolimus dose reductions 4/6 (67) 5/6 (83) 5/11 (45) 14
15 KD : Pharmacodynamics With KD025 treatment: KD025 May Modulate Immune Homeostasis by Restoring the TH17/Treg Balance Treg cells increased TH17 decreased Consistent with KD025 mechanism of action 15
16 KD : Conclusions KD025 Achieved Clinically Meaningful Responses Exploratory Pharmacodynamic Data Support KD025 Mechanism of Action KD025 was well tolerated: No treatment-related SAEs No apparent increased risk of infection Patients achieved NIH-defined clinical responses with KD025 ORRs of 65%, 63% and 52% in Cohorts 1, 2 and 3 respectively CRs in multiple organs, including in organs with fibrotic disease Responses are clinically meaningful: Durable Patients were able to reduce or discontinue corticosteroids and other immunosuppressants Patients experienced clinically meaningful improvement in symptoms (LSS score) Exploratory PD data show a decrease in TH17 and an increase in Treg cells during treatment with KD025 16
17 KD : Ongoing Pivotal Trial of KD025 in cgvhd Objective: Demonstrate clinically meaningful responses with KD025 in a patient population with significant unmet medical need, with an ORR in excess of 30% Key Eligibility Criteria: Adults who have had HSCT Active cgvhd Received at least two prior lines of systemic therapy for cgvhd R KD mg QD (n=63) KD mg BID (n=63) Treat to progression Primary Endpoint: ORR, per 2014 NIH criteria Key Secondary Endpoints: Safety Duration of response Response by organ system Lee Symptom Score Changes in corticosteroid and calcineurin inhibitor dose 17
18 Backup 18
19 KD : Clinical Trial Sites Fred Hutchinson Cancer Research Center University of Minnesota Ohio Oncology Hematology City of Hope Vanderbilt University SCRI: Sarah Cannon Center for Blood Cancer SCRI: Texas Transplant Institute 19
20 KD : Safety and Tolerability (cont.) AST / ALT Elevations Of 13 patients with AST/ALT elevation AEs, 7/13 (54%) had elevations at baseline Elevations were generally low grade, with max Grade 1 in 11/13 (85%) patients None led to treatment discontinuation Dose modifications were rare (1/13 (8%)) 6/13 (46%) were considered possibly drug related Elevations often considered cgvhd-related GGT Elevations Of 10 patients with GGT elevation AEs, 100% (10/10) had elevations at baseline Four of 10 (40%) had their highest measured GGT level prior to initiating KD025 Eight of 10 (80%) had concomitant alkaline phosphatase elevations, a cholestatic pattern often seen with cgvhd liver involvement None led to treatment discontinuation Elevations remained stable in 46% of patients and trended downward in 54% with continued KD025 dosing A Grade 3 elevation in one patient did not recur after restarting KD025 following a 2-week drug holiday 20
Corporate Presentation
Corporate Presentation January 2019 Kadmon Holdings, Inc. 1 Disclaimers This presentation contains forward looking statements that are based on the beliefs and assumptions and on information currently
More informationKD025 in Chronic Graft-Versus-Host Disease (cgvhd)
KD025 in Chronic Graft-Versus-Host Disease (cgvhd) July 11, 2017 1 Kadmon Holdings, Inc. Forward-looking Statement This presentation contains forward looking statements that are based on the beliefs and
More informationCorporate Presentation
Corporate Presentation June 2018 Kadmon Holdings, Inc. 1 Disclaimers This presentation contains forward looking statements that are based on the beliefs and assumptions and on information currently available
More informationKD : A Phase 2 Trial of KD025 to Assess Safety, Efficacy and Tolerability in Patients with Idiopathic Pulmonary Fibrosis (IPF)
-207: A Phase 2 Trial of to Assess Safety, Efficacy and Tolerability in Patients with Idiopathic Pulmonary Fibrosis (IPF) K. F. Gibson 1, F. Averill 2, T.E. Albertson 3, D. M. Baratz 4, S. Chaudhary 5,
More informationKD025 in IPF: Topline Results
KD025 in IPF: Topline Results Webcast Presentation February 13, 2018 Kadmon Holdings, Inc. 1 Forward-looking Statement This presentation contains forward looking statements that are based on the beliefs
More informationAcute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University
Acute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University Graft-versus-Host Disease (GVHD) Background GVHD is an immunologic reaction of the donor immune cells (Graft) against
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationCorporate Presentation
Corporate Presentation November 2016 Kadmon Holdings, Inc. 1 Forward-looking Statement This presentation contains forward looking statements that are based on the beliefs and assumptions and on information
More informationTolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced CLL and NHL
Tolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced and NHL Loretta Nastoupil, MD 1, Matthew A. Lunning, DO 2, Julie
More informationDYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA
DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt,
More informationDuvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia
Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia Susan M. O Brien 1, Manish R. Patel 2,3, Brad Kahl 4, Steven Horwitz 5,
More informationTreatment of Chronic Graft versus Host Disease. Daniel Weisdorf MD University of Minnesota
Treatment of Chronic Graft versus Host Disease Daniel Weisdorf MD University of Minnesota October 2013 Infections Transplant Events d-8 0 1mo 3mo 6mo Conditioning Transplant Engraftment Mucositis Organ
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationWhat from the basket of BTK and PI3K inhibitors?
What from the basket of BTK and PI3K inhibitors? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Associate Professor of Medicine Weill Cornell Medical
More informationNASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference
NASDAQ: TGTX 33 rd Annual JP Morgan Healthcare Conference January 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities
More informationNASDAQ: TGTX Jefferies Healthcare Conference June 2015
NASDAQ: TGTX Jefferies Healthcare Conference June 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More information2/15/18. Biology of Chronic GVHD. Disclosures. Objectives BMT Pharmacists Conference. Paul J. Martin, M.D.
2018 BMT Pharmacists Conference Biology of Chronic GVHD Paul J. Martin, M.D. Member, Fred Hutchison Cancer Research Center Professor of Medicine, Division of Oncology University of Washington Disclosures
More informationManagement of CLL in the Targeted Therapy Era
Management of CLL in the Targeted Therapy Era Jennifer A. Woyach, MD The Ohio State University The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove
More informationLong-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic, 1 MR Migden, 2 AE Oro, 3 L Dirix, 4 K Lewis,
More informationThis was a multi-center study conducted at 44 study centers. There were 9 centers in the United States and 35 centers in Europe.
Protocol CAM307: A Phase 3 Study to Evaluate the Efficacy and Safety of Frontline Therapy with Alemtuzumab (Campath ) vs Chlorambucil in Patients with Progressive B-Cell Chronic Lymphocytic Leukemia These
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationSponsor / Company: Sanofi Drug substance(s): SAR302503
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationG. Socié, MD, PhD Hematology Transplantation Hospital Saint Louis Paris University Paris Denis Diderot & INSERM U728
G. Socié, MD, PhD Hematology Transplantation Hospital Saint Louis Paris University Paris Denis Diderot & INSERM U728 16:00-17:30 Session 7 GvHD Prevention by T-Cell Modulation Is photopheresis treatment
More informationDana-Farber Cancer Institute, Boston, MA, USA; 2 Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 3
Ibrutinib in Combination With Low-Dose Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma: Results From a Multicenter Phase 2 Trial Paul G. Richardson, MD 1 *, William
More informationExpert Review: Updates in Immune Thrombocytopenia. Reference Slides
Expert Review: Updates in Immune Thrombocytopenia Reference Slides Immune Thrombocytopenia (ITP): Overview ITP causality 1,2 Suboptimal platelet production Dysregulated adaptive immune system Increased
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationASCO Annual Meeting 2013, May 31 June , Chicago, IL
Phase I Study of Safety and Pharmacokinetics of GDC-0917, an Antagonist of Inhibitor of Apoptosis Proteins in Patients with Refractory Solid Tumors or Lymphoma 1 A Tolcher, 1 K Papadopoulos, 1 A Patnaik,
More informationM Y ELO I D D I FFER ENTIATI O N OPENS UP THE POSSIBILITIES
IDHIFA (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an
More information(Chronic) Graft Versus Host Disease: When the transplant is just the beginning of the journey
(Chronic) Graft Versus Host Disease: When the transplant is just the beginning of the journey Kitsada Wudhikarn, MD Division of Hematology, Department of Medicine King Chulalongkorn Memorial Hospital Disclosure
More informationFailure-free survival after initial systemic treatment of chronic graft-versus-host disease
From www.bloodjournal.org by guest on November 19, 2014. For personal use only. 2014 124: 1363-1371 doi:10.1182/blood-2014-03-563544 originally published online May 29, 2014 Failure-free survival after
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationNilotinib AEs (adverse events) in CML population:
Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017
More informationASH 2011 aktualijos: MSC TPŠL gydyme. Mindaugas Stoškus VULSK HOTC MRMS
ASH 2011 aktualijos: MSC TPŠL gydyme Mindaugas Stoškus VULSK HOTC MRMS #3042. Yukiyasu Ozawa et al. Mesenchymal Stem Cells As a Treatment for Steroid-Resistant Acute Graft Versus Host Disease (agvhd);
More informationLiver Transplant Immunosuppression
Liver Transplant Immunosuppression Michael Daily, MD, MS, FACS Surgical Director, Kidney and Pancreas Transplantation University of Kentucky Medical Center Disclosures No financial disclosures I will be
More informationConstan'ne S Tam Victorian Comprehensive Cancer Center Melbourne, Australia
Constan'ne S Tam Victorian Comprehensive Cancer Center Melbourne, Australia BGB-3111: Kinase Selec.vity Rela.ve to Ibru.nib Equipotent against BTK compared to ibru.nib Higher selec.vity vs EGFR, ITK, JAK3,
More informationDrug Niraparib Olaparib
Dear NCCN Value Pathway Committee, We are making this submission to provide information that we believe is relevant for developing NCCN Categories of Preference for the use of PARP inhibitors in recurrent
More informationSYNOPSIS (PROTOCOL WX17796)
TITLE OF THE STUDY A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 52-week trial to assess the efficacy and safety of adjunct MMF to achieve remission with reduced
More informationChronic Granulomatous Disease Managing GI Issues
Chronic Granulomatous Disease Managing GI Issues N I C H O L A S H A R T O G, M D D i r e c t o r o f P e d i a t r i c / A d u l t P r i m a r y I m m u n o d e f i c i e n c y C l i n i c A s s i s t
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDisclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida
Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive Non-Hodgkin s Lymphoma P Borchmann Universitaet de Koeln, Koeln,
More informationIN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS WITH BRINCIDOFOVIR: FINAL 36 WEEK RESULTS FROM THE ADVISE TRIAL
TREATMENT OF ADENOVIRUS (AdV) INFECTION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS WITH BRINCIDOFOVIR: FINAL 36 WEEK RESULTS FROM THE ADVISE TRIAL Vinod K. Prasad, MD, FRCP 1, Genovefa A. Papanicolaou,
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationEnasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia
Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia Pollyea DA 1, Tallman MS 2,3, de Botton S 4,5, DiNardo CD 6, Kantarjian HM
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationAcknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center
The Addition of Extracorporeal Photopheresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft- Versus Host Disease in Myeloablative Hematopoietic Cell Transplant (HCT) Anthony Accurso,
More informationMayo Clinic, Scottsdale, AZ, USA; 14 MD Anderson Cancer Center, Houston, TX, USA.
RESULTS OF THE PERSIST-2 PHASE 3 STUDY OF PACRITINIB (PAC) VERSUS BEST AVAILABLE THERAPY (BAT), INCLUDING RUXOLITINIB (RUX), IN PATIENTS WITH MYELOFIBROSIS (MF) AND PLATELET COUNTS 100,000/µL John Mascarenhas
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationCLL - venetoclax. Peter Hillmen St James s University Hospital Leeds 10 th May 2016
CLL - venetoclax Peter Hillmen peter.hillmen@nhs.net St James s University Hospital Leeds 10 th May 2016 Pathophysiology of CLL: Proliferation vs Apoptosis Proliferation Apoptosis Ki-67 Expression Bcl-2
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationACALABRUTINIB IN MCL
ACALABRUTINIB IN MCL Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth UK BRUTON S TYROSINE KINASE (BTK): A CRITICAL KINASE
More informationPCI-32765DBL1002. Janssen Research & Development, Raritan, NJ, USA; 9 Janssen Research & Development, Belgrade, Serbia; 10
Phase 1b Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With CD20-Positive B-Cell Non-Hodgkin Lymphoma (NHL) Anas Younes, 1 Ian
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationPhase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial
Phase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial Jonathan L. Kaufman, Todd Zimmerman, Cara A. Rosenbaum, Anuj Mahindra,
More informationIDWeek 2014, Session: 186, Late Breaker Oral Abstracts Saturday, October 11, 2014, Presentation No. LB 3
IDWeek 2014, Session: 186, Late Breaker Oral Abstracts Saturday, October 11, 2014, Presentation No. LB 3 Preliminary Safety Results and Antiviral Activity from the Open label Pilot Portion of a Phase 3
More informationDepartment of Medicine, Division of Hematology-Oncology, Weill Cornell Medical College, New York, NY 3
The Bruton s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) is Highly Active and Tolerable in Treatment Naïve (TN) Chronic Lymphocytic Leukemia (CLL) Patients: Interim Results of a Phase Ib/II Study
More informationMANIFEST Phase 2 Enhancement / Expansion
MANIFEST Phase 2 Enhancement / Expansion Investor Conference Call Stellar Science, Breakthrough Medicine October 11, 2018 Forward-Looking Statements This presentation contains forward-looking statements
More informationStudy Number CAIN457C2302 (core study) and CAIN457C2302E1 (extension study)
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Uveitis Approved Indication Investigational Study Number CC2302 (core study) and CC2302E1
More informationPharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765
Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325 Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Company to Host
More informationSYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT
Drug product: Drug substance(s): Edition No.: Study code: SYMBICORT pmdi 160/4.5 g Budesonide/formoterol D5896C00005 Date: 8 May 2006 SYNOPSIS A two-stage randomized, open-label, parallel group, phase
More informationPERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey
PERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey Joint Educational Meeting of the EBMT Severe Aplastic Anaemia, Late Effects and Autoimmune Diseases Working Parties
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationPresented by: Adelaide A Hebert, MD UTHealth McGovern Medical School, Houston, TX
Evaluation of the Efficacy, Safety and Tolerability of 4% Once-Daily in Subjects with Moderate to Severe Acne Vulgaris Treated Topically for Up to 52 Weeks A Hebert, J Del Rosso, M Rico, R Woolson, E de
More informationEmricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension
Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension Guadalupe Garcia-Tsao, Michael Fuchs, Mitchell Shiffman,
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More information3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)
3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day
More informationSponsor / Company: Sanofi Drug substance(s): SAR (iniparib)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTisch Cancer Institute, Icahn School of Medicine at Mount Sinai; MPN-RC (US), 2 H Lee Moffitt Cancer Center (US), 3
Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study
More informationBackground. Approved by FDA and EMEA for CLL and allows for treatment without chemotherapy in all lines of therapy
Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Abstract
More informationNon-infectious hepatic complications in patients with GVHD
Non-infectious hepatic complications in patients with GVHD Tapani Ruutu Helsinki University Central Hospital Liver dysfunction in allogeneic stem cell transplantation injury secondary to the cytoreductive
More information15/05/2015. No conflict of interest for this presentation. The first in-class phosphotidlyinositol3-kinase delta (PI3K delta) inhibitor
Disclosure Idelalisib - A Review No conflict of interest for this presentation Pamela Rudkin PhC Hematology Oncology Pharmacist General Hospital Site Eastern Health Care Corporation Objectives At the completion
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationProduct: Blinatumomab (AMG 103) Clinical Study Report: MT Date: 19 April 2013 Page 2 of 9510
Date: 19 April 2013 Page 2 of 9510 2. SYNOPSIS Name of Sponsor: Amgen Research (Munich), formerly Micromet AG/Micromet GmbH, Staffelseestrasse 2, 81477 Munich, Germany Name of Finished Product: Blinatumomab
More informationUnderstanding Myositis Medications
Understanding Myositis Medications 2015 TMA Annual Patient Conference Orlando, Florida Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Disclosures Mallinckrodt: Research Grant Genentech:
More informationI graft-versus-host disease (GVHD) after allogeneic bone
Acute Upper Gastrointestinal Graft-Versus-Host Disease: Clinical Significance and Response to Immunosuppressive Therapy By Daniel J. Weisdorf, Dale C. Snover, Robert Haake, Wesley J. Miller, Philip B.
More informationPresented at the 58 th American Society of Hematology Annual Meeting and Exposition, December 5, 2016, San Diego, CA
1070 Determination of IDH1 mutational burden and clearance via next-generation sequencing in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class inhibitor of
More informationFollicular Lymphoma New Agents. Idelalisib
Indolent Lymphoma Workshop Bologna 2017 Follicular Lymphoma New Agents Idelalisib Sven de Vos, MD, PhD Director, UCLA Lymphoma Program Los Angeles, CA Disclosures of Sven de Vos Company name Research support
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationStudy Rationale. Reference: Chanan-Khan, A., et al., ASH 2010, Abstract#1962. Reference: Whiteman, K., et al, AACR, 2009, Abstract#2799
Phase I Study of Lorvotuzumab Mertansine (LM) in Combination with Lenalidomide and Dexamethasone in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM) Jesus Berdeja 1, Francisco
More informationSecondary efficacy endpoints for Part 2, the Eltrombopag-Only Period, included the proportion of subjects who
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationKEY WORDS: Allogeneic, Hematopoietic cell transplantation, Graft-versus-host disease, Immunosuppressants, Cyclosporine, Tacrolimus
A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells Yoshihiro Inamoto, 1
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationLeukemia. Roland B. Walter, MD PhD MS. Fred Hutchinson Cancer Research Center University of Washington
Leukemia Roland B. Walter, MD PhD MS Fred Hutchinson Cancer Research Center University of Washington Discussed Abstracts Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody
More informationPhase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Jatin J Shah, MD, Sheeba Thomas, MD, Donna Weber, MD, Michael Wang, MD, Raymond Alexanian, MD, Robert
More informationGVHD: new therapeutic approach. Gyd. A. Bukauskas Hematologijos, onkologijos ir transfuziologijos centras VUH Santariskiu Klinikos
GVHD: new therapeutic approach Gyd. A. Bukauskas Hematologijos, onkologijos ir transfuziologijos centras VUH Santariskiu Klinikos Vedolizumab Vedolizumab (Entyvio) monoclonal antibody for the treatment
More informationMayo Clinic, Rochester, Minnesota; 2 Tufts Medical Center, Boston, Massachusetts; 3
NEOD001 Demonstrates Organ Biomarker Responses in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Final Results From a Phase 1/2 Study Morie A. Gertz, 1 Raymond L. Comenzo, 2 Heather
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationPreliminary Results From a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis
Preliminary Results From a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis Tamara K. Moyo, Andrew Sochacki, Gregory D. Ayers, Michael T. Byrne, Stephen A.
More informationONT-380 and HER2+ Breast Cancer
ONT-380 and HER2+ Breast Cancer Diana F. Hausman, MD CMO, VP Clinical Development Oncothyreon Inc. PNW Bio February 10 2015 Copyright 2014 Copyright Oncothyreon 2014 Oncothyreon Oncothyreon Leading Oncology
More informationLow-adherence to recommendations from an authoritative Consensus Conference on trials in cgvhd led to overestimation of treatment effect
Low-adherence to recommendations from an authoritative Consensus Conference on trials in cgvhd led to overestimation of treatment effect Giovanni Pomponio, Jacopo Olivieri*, Lucia Manfredi, Laura Postacchini,
More informationUKALL14. Non-Myeloablative Conditioning Regimen (1/1) Date started (dd/mm/yyyy) (Day 7) Weight (kg) BSA (m 2 )
Non-Myeloablative Conditioning Regimen (1/1) started (dd/mm/yyyy) (Day 7) BSA (m 2 ) Weight (kg) Please enter the daily dose given in the table below: Day Fludarabine (mg) Melphalan (mg) Alemtuzumab (mg)
More information